Savara Inc. SVRA

SVRA Company Overview

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary emphasis is on pulmonary conditions with significant unmet medical need, particularly diseases that currently have limited approved treatment options. Savara operates within the biotechnology and specialty pharmaceutical industries and derives its value primarily from the advancement of proprietary drug candidates through clinical development and regulatory pathways rather than from commercial product sales.

The company’s lead program is molgramostim inhalation solution, developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by impaired surfactant clearance in the lungs. Savara’s strategic positioning centers on orphan and rare disease development, where smaller patient populations may qualify for regulatory incentives such as orphan drug designation and expedited review pathways. Savara originated through the combination and restructuring of several biotechnology assets over time, including prior development-stage respiratory programs, and has evolved into a focused rare pulmonary disease company headquartered in the United States.